Skip to content

the effect of benzocaine-contained tooth paste in decreasing fixed orthodontic pain

Evaluation of the effect of benzocaine-contained tooth paste on relieving orthodontic pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015010120523N1
Enrollment
33
Registered
2015-04-16
Start date
2015-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain percieved after fixed orthodontic appointment. Medical devices associated with adverse incidents in diagnostic and therapeutic use

Interventions

Intervention 1: benzocaine group: 5% benzocaine is added to a commercially available toothpaste, along with 0.075% Aspartam in order to mask benzocaine taste. each patient is given a toothpaste and as
Treatment - Drugs
Placebo
benzocaine group: 5% benzocaine is added to a commercially available toothpaste, along with 0.075% Aspartam in order to mask benzocaine taste. each patient is given a toothpaste and asked to brush his
placebo group: a commercially available toothpaste is filled in identical tube as benzocaine tooth paste and is given to patients. patients are asked to use this toothpaste immediately after appointme
control group: the patients are given a questionnaire with a 0-100 scale to mark their pain 2hours and 6 hours after appointment, at the same night before sleep, at 10am and 6pm on second and third da

Sponsors

Dental Research Center, Research Institute of Dental Sciences of Shahid Beheshti University of Medic
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 20 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patients in leveling and alignment stage who report pain in previous visit; presence of 6-8 crowding; patient informed consent exclusion criteria:history of liver, kidney or allergy to local anesthesia; history of chronic pain and continuous administration of anti pain drugs; presence of dental or mucosal pain; presence of mucosal wound

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: 2 hours and 6 hours after appointment, at the night of appointment, at 10am and 6pm on second and third day and on 10am on 7th day. Method of measurement: visual analogue scale (VAS) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Soheilifar

Shahid Beheshti University of Medical Sciences

se.soheilifar@gmail.com+98 21 2241 3897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026